Remus Pharmaceuticals Limited — Others, 25-04-2025: Structural Digital Database

Remus Pharmaceuticals has shared a compliance certificate confirming adherence to insider trading regulations for the financial year ending March 31, 2025. The certificate, issued by practicing company secretary Tapan Shah, verifies that the company has implemented a Structured Digital Database, ensuring secure access and proper recording of unpublished price-sensitive information (UPSI). With no observed non-compliance issues, the report underlines management's commitment to governance and transparency. This development may reinforce investor confidence by highlighting the company's robust compliance framework and operational integrity, potentially leading to a favorable market perception.